Ovarian Cancer Articles

Frontline Maintenance Olaparib Approved in Europe for Ovarian Cancer
The European Commission has approved olaparib as a single agent for the maintenance treatment of adult patients with advanced BRCA1/2-mutated germline and/or somatic high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response following first-line platinum-based chemotherapy.
Moving Molecular Testing to the Frontlines of Ovarian Cancer
Mihaela C. Cristea, MD, emphasizes the use of molecular testing over tumor testing in ovarian cancer.
Sorting Through Unanswered Questions in Ovarian Cancer
Thanh H. Dellinger, MD, provides insight on the treatment of patients with newly diagnosed advanced ovarian cancer.
SOLO-1 Olaparib Trial Fosters Novel Applications of Frontline Maintenance in Ovarian Cancer
Mihaela C. Cristea, MD, discusses the impact of the SOLO-1 trial on current approaches to frontline maintenance therapy as well as the trials that are underway with niraparib, rucaparib, and the investigational PARP inhibitor veliparib.
Olaparib Extends PFS, Hits High Response in Confirmatory BRCA+ Ovarian Cancer Trial
The PARP inhibitor olaparib reduced the risk of disease progression or death by 38% versus chemotherapy in patients with platinum-sensitive, relapsed, germline BRCA1/2-mutated ovarian cancer who received at least 2 prior lines of chemotherapy.
Niraparib/Bevacizumab Combo Active in Recurrent Ovarian Cancer
A chemotherapy-free doublet for platinum-sensitive recurrent ovarian cancer more than doubled progression-free survival as compared with single-agent PARP inhibitor.
ACA Improved Ovarian Cancer Diagnosis and Time to Treatment
Pre-Medicare-aged women with ovarian cancer were more likely to be diagnosed at an early stage and receive treatment within 30 days of diagnosis after passage of the Affordable Care Act than before.
Work Remains With Immunotherapy in Ovarian Cancer
Daphne B. Stewart, MD, discusses the progress that has been made with immunotherapy in ovarian cancer, provides insight into the focus on combination therapy with checkpoint inhibitors, and explains the impact of negative trials on the field.
Debate Continues Between Primary Debulking and Neoadjuvant Chemo in Advanced Ovarian Cancer
Stephen J. Lee, MD, discusses the trials that have added to existing controversies regarding the optimal management of patients with newly diagnosed advanced ovarian cancer and highlights best practices for deciding between the approaches.
Examining the Underpinnings of PARP Inhibition in Recurrent Ovarian Cancer
Gottfried E. Konecny, MD, shares the known aspects of PARP inhibition in recurrent ovarian cancer.
Publication Bottom Border
Border Publication